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Abstract
This work is motivated by a study of a population of multiple sclerosis (MS) patients
using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to identify active
brain lesions. At each visit, a contrast agent is administered intravenously to a subject and
a series of images is acquired to reveal the location and activity of MS lesions within the
brain. Our goal is to identify and quantify lesion enhancement location at the subject level
and lesion enhancement patterns at the population level. With this example, we aim to
address the difficult problem of transforming a qualitative scientific null hypothesis, such as
“this voxel does not enhance”, to a well-defined and numerically testable null hypothesis
based on existing data. We call the procedure “soft null hypothesis” testing as opposed
to the standard “hard null hypothesis” testing. This problem is fundamentally different
from: 1) testing when a quantitative null hypothesis is given; 2) clustering using a mixture
distribution; or 3) identifying a reasonable threshold with a parametric null assumption. We
analyze a total of 20 subjects scanned at 63 visits (∼30Gb), the largest population of such
clinical brain images.
Keywords: hypothesis testing, soft null, multiple sclerosis, DCE-MRI, contrast enhancement, prin-
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1 Introduction
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system that
results in severe disability and mortality. Localized inflammatory lesions are observed in the
brains of MS patients. The disease is classified into several clinical stages, including relapsing-
remitting MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS)
(Fox et al. , 2006; Lublin & Reingold, 1996). Approximately 85% of patients initially present with
RRMS involving acute attacks. These patients usually recover spontaneously within a few weeks.
Following RRMS, some patients enter SPMS, in which tissue damage accumulates and disability
progresses over time. In contrast, PPMS patients do not spontaneously recover but gradually
worsen after disease onset.
The development of magnetic resonance imaging (MRI) has had great impact on the clinical
management of MS. Characteristics of MS lesions such as volume, number, and location are
crucial. In particular, dynamic contrast-enhanced MRI (DCE-MRI) is used to identify active
white matter lesions through detection of associated abnormalities in the blood-brain barrier.
Such abnormalities are common in patients with RRMS, but rare in subjects with SPMS or
PPMS (Capra et al. , 1992). During each visit, a patient’s brain is scanned to first acquire a few
baseline MR images. After a contrast agent, gadolinium chelate, is administered intravenously,
a sequence of post-injection images are obtained to show which areas of the brain have altered
magnetic properties due to the presence of the contrast agent, observed as increased intensity in
these regions. Post-injection images and pre-injection images are compared to identify unusual
“enhancement” patterns, suggesting localized disruption of the blood-brain barrier and thus lesion
activity.
As an illustration, the top and middle rows of Figure 1 show sagittal slices of T1-weighted
MRIs from two RRMS patients. These images are obtained by measuring the energy emitted by
protons to return to their original state after being excited by a radiofrequency (RF) pulse. The
RF signal decays with an exponential curve characterized by a parameter T1; tissues with different
paramagnetic properties appear differentiated in the image because the signal decay rate varies
by tissue type. Pre-injection images are in the left column, while the middle and right columns
correspond to post-injection images. The bottom row shows the same slice for subject 2 at a
subsequent visit to provide information about disease progression. The estimated lesions shown
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in black contours are obtained from an automatic lesion segmentation algorithm (Shiee et al. ,
2010). From pre- to post-injection images, the intensities of some lesion voxels transition from
dark gray to white. Indeed, the intensity trajectories of voxels throughout the brain have various
spatiotemporal patterns as shown in Figure 2. The various intensity trajectories reflect the varying
characteristics of different tissues. Region-specific patterns are clear: intensities of non-enhancing
lesions and normal appearing white matter (NAWM) stay roughly flat over time, while the blood
vessels have a big jump immediately after the gadolinium injection and then decay quickly. Voxels
in enhancing lesions increase in intensity slowly and remain higher than baseline at the end of the
visit. Even for lesion voxels, the time series can vary dramatically, with newer lesions being more
likely to enhance (Gaita´n et al. , 2011).
Figure 1: Sagittal slices from a DCE-MRI for two subjects acquired at 3 time points before and after contrast
agent injection within one visit. The images were acquired at 7 minutes before injection, and 4 and 32 minutes
after injection. The black contours depict estimated lesions using Lesion-TOADS. First row: subject 1; second
and third rows: subject 2 at two consecutive visits. One lesion of subject 1 and the ring-shaped lesion of subject 2
gradually light up over time. However, the ring-shaped lesion enhances less at the follow-up visit.
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Our scientific interests focus on identifying newly developed lesion voxels based on their inten-
sity curves, and quantifying their enhancement patterns. The current practice of visual inspection
by trained radiologists is effective for targeting enhancing lesion as a whole, but remains qualitative
and prone to error, especially for smaller lesions and more subtle enhancement patterns. Quanti-
tative methods for describing the temporal structure and identifying enhancing lesion voxels are
important for clinical practice and for advancing our understanding of MS pathophysiology.
Figure 2: Time series of voxel intensities in different regions of the brain from one visit. Voxels are randomly
selected from the groups classified by the segmentation algorithm. Blood vessel voxels are selected based on visual
inspection of images. Left axis: raw intensities; right axis: normalized intensities; x-axis: time in minutes.
1.1 Experimental Design and Data Description
At each study visit, we obtain a series of T1-weighted images before, during, and after injection
of the contrast agent. All images are registered to the Montreal Neurological Institute (MNI)
standard space. We then use a skull-stripping procedure (Carass, 2007) to remove voxels that
4
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are outside the brain. The Lesion-TOADS algorithm (Shiee et al. , 2010) automatically segments
brain tissues including cerebrospinal fluid, gray matter, white-matter (WM) lesions and normal-
appearing white matter (NAWM).
In this study, we consider 63 DCE-MRI datasets from 20 subjects. Among these patients, 4
were diagnosed with PPMS and the remaining had RRMS. Each dataset was recorded at a single
study visit and many subjects were observed over multiple visits. During each visit a different
number (11 to 19) of T1-weighted images were recorded up to 74 minutes after the injection. One
male subject (subject 1) was observed over 155 mins after injection at one single visit, and 67
images were acquired to assess long-term enhancement behaviors. The T1-weighted images from
each visit are stored in a 4-dimensional array. The first 3 coordinates represent the right-left,
posterior-anterior, and inferior-superior axes and are of dimension 182 × 218 × 182 for a total of
more than 7 million entries. The 4th dimension is the time at which the images are acquired during
the visit and varies by scan. The largest DCE-MRI for a subject at one visit in our dataset had
almost 500 million data points, while an average DCE-MRI had roughly 100 million entries. The
time points are calibrated so that the contrast agent injection occurs at time 0. The segmentation
information is stored as 3-dimensional binary arrays indicating which voxels correspond to which
tissue type. To avoid any misunderstanding, it is worth mentioning that DCE-MRI is a completely
different modality from functional Magnetic Resonance Imaging (fMRI). The scientific problems
addressed using DCE-MRI are fundamentally different from those of fMRI. To the best of our
knowledge, there is currently no publication in the statistical literature dedicated to one full-brain
DCE-MRI, not to mention populations of such images.
1.2 Previous Work
The state-of-the-art for analyzing DCE-MRI is to apply pharmacokinetic (PK) (Davidian & Gilti-
nan, 1995) models at every voxel (Tofts et al. , 1999; Yankeelov et al. , 2005; Li et al. , 2005).
Through a set of PK parameters, the model connects the observed intensity time course with
dynamic concentration of contrast agent and tissue characteristics (Tofts et al. , 1999). The ex-
tracted tissue characteristics are then used to identify abnormal behavior in lesions. The appeal
of PK models for DCE-MRI is that they are intuitive, simple, well-understood, and derived from
well-defined physical models. However, PK models fail on more than 80% of the brain voxels in
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our example. Perversely, they fail exactly where quantification is most important: in areas of
moderate and small enhancement in and around lesions. A quick inspection of the data displayed
in Figure 2 should explain why this is the case: models that work in the middle of the lesion
may be completely inadequate in the normally appearing white matter, blood vessels, or areas
immediately surrounding the lesion. When the focus is on estimating the extent and type of le-
sion enhancement, this is a fatal flaw. Moreover, PK models make assumptions that are hard to
defend in practice: in particular, that a fixed number of compartments is enough for every voxel
irrespective to their tissue types. Our experience is that the standard single-compartment PK
model works well in practice after lesions are identified and only for those voxels with pronounced
enhancement. Here we are concerned with automatic identification of voxels that enhance and
characterization of enhancing behavior along its continuum: no enhancement, small, moderate
and strong enhancement.
Another problem is that standard approaches focus on analyzing one subject at a single
visit. Here, we are interested in characterizing populations of such visits and characterizing the
population-level structure of enhancement patterns. Shinohara et al. (2011) proposed a different
approach using functional principal component analysis (FPCA) to extract population-level fea-
tures of lesion enhancement. Using data from 10 subjects observed cross-sectionally, their work
suggested that lesion enhancement patterns were captured by two principal components. In our
paper, we first perform a confirmatory analysis of the findings in Shinohara et al. (2011) using a
dataset that is roughly 6 times larger. We then focus on our main goal: designing a null hypoth-
esis and a test that are consistent with the visual inspection (qualitative assessment) in finding
enhancing lesion voxels. Once this is done in several subjects we investigate the generalizability
of our approaches to other subjects.
1.3 Soft Null Procedure
The classical hypothesis testing aims to assess the congruence of the observed data with a formal
and testable hypothesis of interest, which we refer to as a “hard” null hypothesis. However in our
example, one qualitative scientific hypothesis may be interpreted in varying ways which correspond
to a set of rigorously defined null hypotheses. Defining and choosing a hard null hypothesis is
difficult and the result may depend heavily on this choice.
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We propose using soft null hypotheses as a framework for assisting the transition from a
scientific notion to a well-defined hypothesis that is appropriate for testing. In this procedure,
data play an important role in generating, refining and selecting this hard null from a sequence of
candidate “soft” null hypotheses. Although current investigators may have been using information
from data, consciously or not, to build up hard null hypothesis, the framework that we describe
formalizes this process and highlights its importance. The soft null procedure consists of the
following steps: 1) quantify the qualitative hypothesis, which provides a likely set of candidate
null hypotheses; 2) test the candidate hypotheses on a training dataset; 3) based on the testing
results, reevaluate the the candidate hypotheses and generate more refined hypotheses; 4) identify
a few hypotheses as suitable hard null hypotheses; 5) test the hard null hypotheses on test data
in the classical inference paradigm. Using the application of lesion enhancement detection to
illustrate the details of soft null procedure, we aim to add some structure and statistical rigor
to “hypothesis generation”, which is an ill-defined process usually left to scientist who are not
assisted by statisticians.
Specifically, our objective is to refine quantitative approaches to testing enhancement at the
voxel level. Figure 1 indicates that many parts of the brain, such as the blood vessels and meninges
also enhance. Moreover, lesion locations are not accurately estimated. Thus, defining the null
hypothesis of normal intensity change in lesions is difficult. The problem with identifying a
mathematically rigorous null hypothesis stems from how we naturally treat information. For
example, the word “enhancement” qualitatively describes a physical property of brain tissue as
it characterizes a transition from shades of black to shades of white in images, such as in Figure
1. However, precise formulation of “enhancement” needs to undergo a process of generating and
refining the definition of possible null hypotheses. In Section 4, we investigate five biologically
meaningful working null hypotheses and estimate the associated null distributions. Three of the
definitions are based on visit-specific data and two are based on population-level analyses. These
definitions of the null hypothesis corresponding to “no enhancement” have different interpretations
and incorporate various levels of additional information.
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2 Validation of Established Techniques
Two problems must be addressed before testing for enhancement. First, raw MR intensities are
not normalized within or across subjects, making population-level analyses and generalizations
difficult. Second, data are very large and require dimensionality reduction. For the first problem,
Shinohara et al. , 2011 proposed normalization with respect to NAWM intensities measured before
gadolinium injection. The procedure is simple and intuitive, only requiring data within the same
visit. For the second issue, Shinohara et al. , 2011 used PCA of all voxel-level time series across
10 subjects. They conclude that: 1) the first four principal components (PCs) explain more than
99.8% of total variability; 2) two principal components capture lesion-enhancing behavior; and 3)
analyzing the scores of these two principal components enables quantifying time series behavior
across regions of interest. We deploy their approach on a much larger dataset (63 versus 10 scans),
and investigate the reproducibility of conclusions made in this previous work.
In particular, the images are normalized as Yi(t, v) =
Y Oi (t,v)−µi,0√
Vi,0
, where Y Oi (t, v) is the raw
intensity of voxel v at within-visit time t in visit i, Yi(t, v) is the associated normalized intensity,
and µi,0 and Vi,0 are the sample mean and variance for the pre-injection intensities of all NAWM
voxels. In addition, the inconsistent imaging acquiring time across visits enables us to characterize
population-level features in the data throughout the scanning period, particularly during the first
hour. Given the sparsity of the sampling grids across subjects, we smooth the time series for each
voxel at every visit using linear interpolation as suggested by Shinohara et al. (2011) and obtain
intensity measurements on an equally-spaced time grid. The details are omitted here.
After normalizing the intensity and interpolating the time series, we conduct population-level
PCA to capture the temporal patterns of voxel intensities in different brain regions. The first
nine population-level principal components (PLPC) (Figure 3) resemble those obtained in smaller
sample size. As the earlier data is a subset of our dataset, we conduct the same analysis excluding
those in Shinohara et al. , 2011 and obtain similar results (omitted). Smoothing the covariance
operator may be done before eigenvalue decomposition. However, this was unnecessary due to the
large number of voxels and dense sampling across subjects.
The first four PLPCs explain more than 99.5% of the total variance. PC 1 is flat over time and
accounts for heterogeneity of baseline intensities across different brain regions. The second PC
describes an instantaneous increase in voxel intensity after injection, reflecting contrast dynamics
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Figure 3: The first nine principal components from the population-level analysis of the 63 visits are shown in
blue lines. The numbers in percentage at the bottom right corner are the proportions of variance explained by each
component. The dashed red lines show the first nine PLPCs obtained by the 10-subject analysis from Shinohara
et al. , 2011. The first four curves are almost identical. Since the PC components are invariant with respect to
sign, the 5th to the 7th components from the 10-subject results were flipped to match with the PLPCs from the
larger analysis.
in blood vessels (see, for comparison, the bottom right panel in Figure 2). The third PC displays a
slow increase over time and corresponds to the gradual brightening of some voxels within enhancing
lesions. The fourth component shows a fast increase followed by a fast decline in voxel intensity,
peaking at approximately 30 minutes after injection. After the PLPCs have been estimated, the
PC scores for voxel v in dataset i are obtained as ξik(v) = 〈Yi(t, v), φk(t)〉 ≈
∑T
i=1 Yi(ti, v)φk(ti),
where Yi(t, v) is normalized intensity at time t for voxel v of subject i. The scores are then mapped
back to the brain (Figure 4) where spatial correlation is reconstructed. Figure 4 displays maps
of the first 4 PC scores for visit 1 of subject 2 (middle panel of Figure 1) on four different slices,
9
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(a) PC score 1 (b) PC score 2
(c) PC score 3 (d) PC score 4
Figure 4: PC score images in the brain of the second subject in four sagittal slices. Voxels with high 2nd PC
scores are mostly in blood vessels. Some lesions (within the black contours), however, also have high PC2 scores.
The ring-shaped lesion contains voxels with high PC3 and PC4 scores, but some of the voxels near the back of the
brain have have similar scores.
confirming interpretation of the PLPCs. We conclude from Figure 4 that voxels which gradually
enhance over time have high projections on the 3rd and 4th PCs.
To quantify enhancement, we restrict our analysis to the bivariate PC score space Si =[ {ξi3(v), ξi4(v)}, v = 1, 2, ..., Vi]. The left panel of Figure 5 displays scatter plots of these pairs
of PC scores for 5 subjects (each subject shown in a different color). These plots contain a dense
central area with long right tails shooting towards the top-right corner of the plot. Thus, in this
space, the problem becomes finding a null hypothesis and a decision boundary that discriminates
between lesion enhancement voxels and other voxels. We argue that this problem requires care-
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ful hypothesis development, testing on data, followed by refinement of both hypothesis and test
statistics. As no statistical textbooks discusses this data-based process that applied Statisticians
have been using forever we contend that this is a new theoretical concept.
3 Clustering with Mixture Distributions
In the search for the right testing framework we start with a comfortable approach: using mixture
distributions and hoping for the best. Consider the case when we fit a sequence of mixtures of
bivariate normal distributions for one of the subjects corresponding to an increasing number of
mixture components. The right panel of Figure 5 displays results from fitting a mixture of 2
bivariate normal distributions. The solid-black ellipsoids indicate the contours of one standard
deviation away from the mean for the two normal distributions. The number of voxels that are
estimated to enhance (the blue dots) is very large. Plotting these voxels back on the brain template
would provide a case of the “blue brain”, one that is estimated to enhance almost everywhere.
We have also conducted clustering with three to six components. Given the huge number of
voxels in the brain, a larger number of components is always preferred using standard criteria.
However, even with an increased number of clusters, identifying the cluster of enhancing lesion
voxels remains elusive (See supplementary materials for details). An additional practical difficulty
is that as we increase the number of clusters, cluster assignments of voxels change dramatically.
In this context using FDR instead of Bonferroni correction would be an even worse approach
because it would simply allow for more voxels to be estimated as enhancing. This is a fundamen-
tally different problem from the studies discussed in Efron (2004, 2007). In their case the problem
is to allow for a more liberal α level in situations where the signal is very weak. Here we are
dealing with millions of voxels that do not enhance at all, most of which are concentrated around
the origin, mixed with hundreds of thousands of lesion- and non-lesion voxels whose patterns of
enhancement span the continuum from very subtle to ultra-obvious. From a statistical perspec-
tive we are thus confronted with a subject-specific complex mixture of an unknown number of
distributions with unknown characteristics. To our knowledge, no such problem has been posed
and standard statistical approaches do not provide a solution. Without a rigorous definition of
“non-enhancement” that can pass visual inspection of data and results, we quickly run into circu-
lar logic. In the next section, we will take the testing approach and consider a sequence of working
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null hypotheses that quantify the scientific hypothesis of detecting enhancing lesion voxels.
Figure 5: On the left panel shows the scatterplot of 3rd and 4th PC scores from 5 subjects and 1 visit per subject.
Voxels in WM masks are colored by visit, and other voxels are shown in gray. Most of the dots are concentrated
around the origin, meaning that the majority of voxels have relatively small PC 3 and 4 scores; While a small
group of voxels have extreme PC scores, shown in the plot as the arms shooting towards the upper-right corner.
Also note that data from 5 subjects overlap with each other quite well, which suggests that the normalization
procedure corrects most of the heterogeneity across different data. On the right we have the clustering results
using a mixture of two bivariate normals for the 3rd and 4th PC scores from one dataset. Two ellipsoids: the two
normal distributions (mean plus one standard deviation). Red dots: estimated non-enhancing voxels. Blue dots:
estimated enhancing voxels. Bonferonni correction was used.
4 Testing for Enhancement
Through statistical hypothesis testing, we aim to determine voxels that enhance abnormally, a
behavior associated with active inflammation in newly formed lesions. However, we identified
two main difficulties: lack of a precise definition of non-enhancement and lack of methods for
estimating the associated null distribution. Generally considered a purely scientific endeavor, the
first problem is more difficult and conveniently dismissed.
In this section, we navigate through several definitions of non-enhancement and propose simple
12
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methods for estimating the corresponding null distributions. We first present a spectrum of null
hypotheses specific to each dataset, starting with the narrowest definition of non-enhancement
and expanding towards more liberal definitions. Each null hypothesis corresponds to our scientific
goal of enhancement detection, but each leads to fundamentally different interpretations. We also
consider two null hypotheses defined across subjects that incorporate population heterogeneity.
4.1 Null distribution based on a single visit
We propose several approaches that define null distributions estimable from the data measured at
a single study visit. Such a visit-specific null distribution avoids issues caused by inappropriate
normalization across subjects and visits.
4.1.1 H0,1 Counterfactual Null
We first consider the following null:
H0,1: voxel-specific time series dynamics is the same before and after contrast injection
Let Yi(t, v) be the intensity of voxel v at time t at visit i, µi,<0(v) and σ
2
i,<0(v) be the voxel-specific
mean and variance of intensities measured before time 0 (injection). For voxels where H0,1 holds,
their intensity should have the same distribution before and after injection. In particular, these
voxels will have the property A1,i :=
{
v : E[Yi(t, v)] = µi,<0(v) , V ar[Yi(t, v)] = σ2i,<0(v) for all t
}
.
We call H0,1 the counterfactual null hypothesis because it defines non-enhancement based on the
intensity time series of voxels when gadolinium injection is absent (not observed in our study).
We now focus on estimating the bivariate distribution of the 3rd and 4th PC scores for non-
enhancing temporal patterns under H0,1. We assign each voxel a non-enhancing ‘match’ by simu-
lating a counterfactual time series based on pre-injection observations:
Y nulli (t, v) = µ¯i,<0(v) + si(t, v), (1)
where µ¯i,<0(v) =
1∑
t I(t<0)
∑
t<0 Yi(t, v) is the averaged pre-injection intensity that estimates µi,<0(v),
I(t < 0) is the indicator function for t < 0, and si(t, v) is randomly sampled from the collection
of residuals of all the voxels before time 0; namely, si(t, v) ∈ {ri,<0(u) = Yi(s, u) − µ¯i,<0(u) : s <
0, u = 1, 2, · · · , Vi}. Figure 6(a) displays 7 sample time series from the original dataset together
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with their simulated counterfactual ‘matches’. This procedure assumes that the errors deviating
from the pre-injection mean are white noise and follow a common distribution across all voxels.
Figure 6(b) supports this assumption as the standard deviation of the pre-injection intensities for
each voxel is roughly independent of its mean and does not vary across tissue types.
(a) (b)
Figure 6: (a) Time series of seven voxels from a single subject and their counterfactual curves generated under
H0,1. (b) Standard deviations of {ri,<0(v)} (y-axis) versus µ¯i,<0(v) (x-axis). Each point corresponds to one
voxel in the brain. The left axis is in the raw intensity scale and the right axis is in the normalized scale. The
color indicates tissue types according to the segmentation information available. Black dots are the coefficients of
variation calculated for each voxel. The standard deviation does not seem to depend on the tissue type or on the
mean intensity.
After simulating the non-enhancing counterpart for all voxels Y˜i := {Y nulli (t′, v)}Vi×T , we
project them onto the kth (k = 3, 4) component space and obtain the ‘nullified’ PC score for voxel
v as ξnullik (v) := 〈Y nulli (·, v), φk(·)〉 ≈
∑
t Y
null
i (t, v)φk(t). We then estimate the density of the null
distribution based on {ξnulli3 (v), ξnulli4 (v)}. For our analysis, we fit a bivariate normal distribution
N(û, Σ̂) to these scores. The p-value for voxel v can be interpreted as the probability of observing
a sample from N(û, Σ̂) that is more extreme than {ξ3(v), ξ4(v)}. Specifically, we define:
14
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pv =

Φ
(
ξ3(v) < ξ3, ξ4(v) < ξ4|û, Σ̂
)
, if ξ3(v) > u3 and ξ4(v) > u4;
Φ
(
ξ3(v) < ξ3, ξ4(v) > ξ4|û, Σ̂
)
, if ξ3(v) > u3 and ξ4(v) ≤ u4;
Φ
(
ξ3(v) > ξ3, ξ4(v) < ξ4|û, Σ̂
)
, if ξ3(v) ≤ u3 and ξ4(v) > u4;
Φ
(
ξ3(v) > ξ3, ξ4(v) > ξ4|û, Σ̂
)
, if ξ3(v) ≤ u3 and ξ4(v) ≤ u4.
(2)
where Φ(·|û, Σ̂) is the cumulative distribution function of N(û, Σ̂) with û = (u3, u4)T . At 95%
confidence level under Bonferroni correction, we reject H0,1 for voxels whose pv < 0.05/Vi, where
Vi is the number of voxels for subject i and is typically in the millions. Given the observed strong
enhancement patterns in the brain, doing a Bonferonni correction is not too conservative. On the
contrary, we believe that a correct definition of the null hypothesis is the single most influential
factor in concluding scientific results. We exclude voxels with negative ξ3 or ξ4 since we are only
interested in those with high scores. R1,i =
{
v : pv < 0.05/Vi, ξ3(v) > 0, ξ4(v) > 0
}
is the rejection
region.
Figure 7 summarizes the testing results of H0,1 for the first subject. In 7(a), the p-value of
each voxel is coded using the color scheme shown in the legend. The red dots are amplified for
clarity. The black ellipsoid indicates the Bonferroni-corrected 95% confidence region for the null
distribution under H0,1. Figure 7(b) shows the location of the rejected (enhancing) voxels in four
different slices of the brain. On slice 65, part of lesion 1 is successfully identified with extremely
small p-values. Some voxels in the second lesion are also selected (shown in slice 72). On slice
96, a group of orange dots near the forehead indicates an enhancing lesion that was not detected
by the automated lesion segmentation method, but is discovered by our method. It was later
confirmed through visual inspection by an expert neuroradiologist with extensive experience with
MS. In 7(d), we stratify the voxels into four groups by their p-values, draw 20 random samples
from each group and plot their time series (shown in color corresponding to p-value) as well as the
average intensity curve (black). Small p-value (i.e. significant result in the testing) is consistent
with large degree of enhancement in the observed time series.
This approach works reasonably well. However, we find that {ξnull3 , ξnull4 } are highly concen-
trated around the origin and Σ̂ is quite small (the black ellipse in 7(a)). This results in a rejection
region that is too large and leads to many false positives; see Figure 7(b). More precisely, in
this example, H0,1 is rejected at 5.7% of the whole-brain voxels. Among the rejections, 0.88% are
15
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(a) (b)
(c) (d)
Figure 7: Analysis results of data for subject 1 using the counterfactual null. (a) The p-value of each voxel is
represented in color and the size of red dots are amplified for clarity. The black ellipsoid is the 95% confidence
contour under the Bonferroni correction using the total number of voxels that are tested; (b) The location of rejected
voxels in four different slices of the brain. Slice 65 shows that voxels in the enhancing lesion are successfully
classified. Slice 72 shows that part of another lesion is also identified. There are quite a few white matter voxels
that are selected in slice 90. On slice 96, a group of orange-colored voxels correspond to an enhancing lesion that
is not detected by the automated lesion segmentation method, but is discovered by our method; (c) Voxels that are
in the white-matter mask and have significant p-values, shown on the same four slices as in (b); (d) We stratify
the voxels by their p-values into four groups and draw 20 random sample series in each group. The trajectories
shown in color are the observed time series and the mean curve in black. The upper-left graph shows voxels that
are not deemed enhancing.
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labeled as “within-lesion” by the Lesion-TOADS algorithm, 0.83% are in the NAWM mask and
the rest fall outside the white matter mask. In fact H0,1 is rejected in many regions that are not
of biological interest, including blood vessels, non-enhancing lesions and even NAWM (see, for
example, slice 90 in 7(b)). We conclude that pre-injection behavior of a voxel cannot accurately
approximate its post-injection behavior, even if that voxel is not in an enhancing lesion. If we
constrain the candidate voxels to be within the white matter mask, many false positive voxels can
be excluded; for example, comparing Figure 7(c) with 7(b) indicates that such a procedure would
eliminate the voxels near the meninges or around larger veins. However, many of the voxels of
the new lesion that we identified in the forehead would also be excluded, which would prevent a
scientific finding. An additional problem with this type of analysis is that white matter masks
from automated methods such as Lesion-TOADS are far from perfect and in many studies may
not even be available. Therefore, we remain on the whole-brain analysis.
Although the counterfactual null is liberal for detecting enhancing lesions, it provides us an
unique exploratory tool that assists in understanding the actual enhancement mechanism and
quantifying enhancement pattern from a single scan when no other segmentation information is
available. Indeed, the testing results from H0,1 motivate a new set of hypotheses H0,2 and H0,3
which account for the intensity change in normal regions.
4.1.2 H0,2 NAWM-based Null
We have seen that even voxels in NAWM may become brighter after the gadolinium injection and
have positive 3rd and 4th PC scores. This is due to normal blood flow to the tissues through
capillaries or small vessels. To diminish false positives, we need to account for these normal
intensity changes when building null hypotheses. This is possible when a NAWM mask is available
(from a segmentation algorithm) for each visit. Our null hypothesis may then be expressed as:
H0,2: the voxel-specific time series dynamics is the same with those of NAWM voxels
As a result, for voxel v0 where H0,2 is true, {ξ3(v0), ξ4(v0)} follows the same distribution as in
A2,i := {[ξ3(v), ξ4(v)], v ∈ NAWM}. As the true NAWM segmentation is unknown, we estimate
A2,i by Â2,i =
{
[ξ3(v), ξ4(v)], v ∈ NAWM masks estimated by the Lesion-TOADS algorithm
}
.
Similar to the previous approach, we estimate the null distribution by fitting a bivariate normal
to Â2,i and calculate p-values for each voxel.
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(a) (b)
(c) (d)
Figure 8: (a-b) Analysis results of data for subject 1 using the NAWM-based null H0,2. (a) The p-value of each
voxel is represented in color and the size of red dots are amplified for clarity. The black ellipsoid is the 95%
confidence contour under the Bonferroni correction using the total number of voxels that are tested. A much
broader confidence region is generated than Figure 7(a). (b) The location of rejected voxels in four different slices
of the brain. Note that less white matter voxels are selected on slice 72 compared to Figure 7(b). Nevertheless, the
enhancing voxels in lesion mask and in the detected enhancing lesion missed by Lesion-TOADS are still selected.
(c-d) Analysis results of data for subject 1 using the complementary null H0,3. This approach is more conservative
in terms of defining enhancement compared to the first two null hypotheses. Note that on slice 72 in (d), voxels
in the second lesion are no longer significant.
Compared to the counterfactual null, H0,2 generates a much broader 95% confidence region
(black contour in Figure 8(a)). For the same data from subject 1, 2.38% of the voxels in the brain
are rejected, among which 1.4% are in the lesion masks and 0.19% are in the NAWM mask. The
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main difference between Figure 7(b) and 8(b) is on slice 90 where most of the NAWM voxels that
are identified as enhancing in H0,1 are filtered out when testing H0,2. While selecting fewer false
positive voxels, the enhancing voxels in the lesion areas are still identified and are shown on slice
65, 72 and 96 of Figure 8(b).
4.1.3 H0,3 Complementary Null
H0,2 successfully identified enhancement in lesions and eliminated most of the NAWM voxels
falsely classified using the counterfactual null. However, it fails to separate voxels in the enhancing
lesions from those in blood vessels and around the meninges. We conclude from Figure 5 that this
is inevitable if we base our analysis only on {ξ3(v), ξ4(v)} but no additional information. This is
because the PC scores for voxels outside the WM mask (gray dots in Figure 5) spread as widely as
lesion voxels (the upper-right tail of the colored dots). To solve this, we consider including both
NAWM and voxels outside white matter in the null distribution estimation. The corresponding
null hypothesis for this case is:
H0,3: the voxel-specific time series dynamics is the same with that of non-lesion voxels
We call H0,3 the complementary null because it is defined based on the complement set of the
lesion masks where we are interested in searching for enhancement. We denote the null set of PC
scores under H0,3 by A3,i :=
{
[ξi,3(v), ξi,4(v)], v is not in lesions
}
. Similar to H0,2, we estimate
A3,i by
{
[ξi,3(v), ξi,4(v)], v /∈ lesion masks
}
.
The bottom row of Figure 8 shows the results from applying the test to the first subject.
Compared withH0,2, a smaller number of voxels (0.37% of the whole brain) are rejected and a larger
proportion (4.03%) of the rejections are located in the lesion masks. H0,3 is more conservative
in terms of defining enhancement compared to the first two null hypotheses and generates the
smallest rejection region among the three visit-specific null hypotheses. On slice 72 in 8(d), voxels
in the second lesion are no longer selected as significant, but the forehead lesion is still detected.
In addition, the number of false positive voxels around the edge of the cerebrum and in the vessels
is greatly reduced. Note that through comparing the testing results of different null hypotheses
using data from one subject and combining it with spatial information, we are able to better
understand the qualitative scientific null hypothesis.
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Both H0,2 and H0,3 rely on the segmentation masks for each dataset. A natural question
would be: how much do results depend on the segmentation accuracy? Indeed, given a perfect
lesion segmentation we could restrict our analysis to the lesion mask. However, all segmentation
algorithms are imperfect. Instead of applying the lesion masks to filter the final testing result,
we incorporate the mask in the null distribution estimation. We believe that the segmentation is
correct for most of the voxels and the correctly labeled voxels form a representative sample from
the population. As a result, density estimation is not severely biased by the misclassification.
In fact, the testing results can conversely be used to tune the segmentation algorithms. For
example, as shown in the supplementary document, testing results for subject 2 reveals that one
lesion on slice 109 has an enhancing region that lies outside the original lesion mask. After visual
inspection our collaborators indicated that the mask was indeed flawed and that our approach
correctly identified the extent of the lesion enhancement.
As we progress from H0,1 to H0,3, the definition of null hypothesis is refined and various
comparisons across the results can be investigated. The sequential hypotheses testing procedure
unveils various degrees of dynamic changes in voxel intensities throughout the brain. Despite the
consistency in detecting lesion 1 as well as the frontal lobe lesion, the associated non-rejection areas
at the same α-level become larger and the proportion of rejections in lesion masks increases in
accordance with visual inspection. If interest lies in a more liberal partition of voxels which detects
diffuse enhancement throughout the brain, then H0,1 may be ideal. However, if isolating lesion
voxels that have dramatic enhancement properties is the goal, H0,2 or H0,3 are more appropriate.
The scenarios presented in this section are defined within a single DCE-MRI dataset. In most
studies, however, data from multiple subjects and visits are collected; in the next section we
consider using data across subjects to define non-enhancement.
4.2 Population-level Null Distribution
Incorporating information from multiple subjects and visits is key in classical statistical problems
for evaluating variability in a population. Here, we consider formulating null hypotheses that
borrow strength across datasets to estimate null distributions.
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4.2.1 H0,a NAWM across Samples
We start with an approach that is similar to H0,2. Using data from multiple subjects accounts for
population heterogeneity that is not addressed by normalization. It also allows us to apply the
estimated null distribution directly to future images acquired under the same protocol and avoids
requiring segmentation results for the particular visit being analyzed. In particular, we define the
null hypothesis in terms of the intensity behavior from voxels in the NAWM masks of all datasets
other than the testing data.
H0,a: the voxel-specific time series dynamics is the same with with those of NAWM
voxels in the population
Let Aa :=
{
[ξj,3(v), ξj,4(v)], INAWM(v) = 1, J ∈ I\{i}
}
, where J is the index for all datasets. To
estimate the null distribution under H0,a, we fit a normal distribution to the 3rd and 4th PC scores
for all voxels which are classified as NAWM from visits other than the one to be tested. We then
apply the testing procedure developed previously. Taking the first subject as an example (results
shown in the upper row of Figure 9), we reject 0.47% of the voxels in the brain, among which 3.52%
are in the lesion mask and 0.34% are in the NAWM mask. With a larger number of voxels that can
be used for density estimation, this paradigm provides more stable results than the visit-specific
cases from Section 4.1. Compared with H0,2 (Figure 8(b)), H0,a classifies far fewer voxels around
the meninges and vessels as “enhancing”. Even though these voxels are not contained in the
NAWM masks and do not contribute in estimating the null distribution, their temporal patterns
are correctly identified as null. This is due to the incorporation of population-level variation in
the NAWM. But this approach does not consider variation across other brain areas. To address
this, we consider analyzing the normal variation across brain using control subjects in the next
definition.
4.2.2 H0,b PPMS as Control
In order to detect differences in temporal patterns of abnormally enhancing MS lesions, one may
also consider comparing the whole brain to controls. The ideal option would be to study DCE-
MRI scans in healthy subjects. But the injection of a contrast agent is not completely risk-free
and thus unethical to healthy subjects. One way around the problem is to identify subjects who
were scanned, but whose DCE-MRI would be expected to be closest to that of a healthy brain.
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(a) (b)
(c) (d)
Figure 9: Results of testing the first subject data on the population level null H0,a (a-b) and H0,b (c-d). H0,b
provides a more conservative estimation of null distribution than H0,a.
As described in the introduction, lesion enhancement on DCE-MRI is seen primarily in RRMS
patients, but seldom in PPMS subjects (Capra et al. , 1992). Thus, subjects with PPMS provide
an alternative population that may be used as controls. Figure 10 compares the 3rd and 4th PC
scores for all of the PPMS subjects (left) in our dataset and four randomly chosen subjects with
RRMS. The red dots represent voxels in the lesion masks. Note that the PC scores for PPMS are
concentrated around the origin while dots for RRMS lesions tend to exhibit arms shooting towards
the top-right corner, indicating high PC 3 and PC 4 scores corresponding to enhancement. There
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are, however, some RRMS visits (the bottom-left plot in the right panel) without such arms,
indicating subjects that are free of enhancing lesions at the time.
We formulate the null hypothesis with respect to PPMS patients as
H0,b: the voxel-specific time series dynamics is the same with with those of brain voxels
of PPMS subjects
(a) PPMS (b) RRMS
Figure 10: Scatterplots of PC 3 vs. PC 4. The left sub-figure shows four PPMS subjects and the right one
shows four RRMS subjects. The red points correspond to voxels in the lesion masks, the blue points are in the
NAWM mask and the grey dots represent other voxels in the brain. Note that the PC scores for PPMS are
concentrated around origin while those for RRMS subjects deviate farther from the origin. Typically, voxels in
the lesion mask of the RRMS data have arms shooting towards the upright corner, indicating high PC3 and PC4
scores in enhancing lesions. However, there are also some RRMS subjects (such as that depicted in bottom left
of (b)) without enhancing lesions which thus lack these arms.
A closer look atH0,b indicates that voxels from the PPMS subjects are implicitly assumed to ex-
hibit all the normal temporal behaviors except those corresponding to lesion enhancement. We also
assume that voxels from RRMS patients follow a mixture distribution of these normal behaviors
and enhancement behaviors. We obtain the stable density estimation of null distribution by fitting
a normal distributionN(µ̂PPMS, Σ̂PPMS) to PC scores inAb =
{
[ξj,3(·), ξj,4(·)], j is a PPMS patient
}
.
As before, we can conduct hypothesis testing on any data acquired using this protocol.
As the bottom row of Figure 9 shows, this approach seems to be quite conservative compared
to the previous methods. When applied to subject 1, fewer voxels (only about 0.47%) of the brain
are selected as enhancing. Among them 3.5% are in the lesion mask and 0.34% are in the NAWM
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mask. Voxels in lesion 2 are no longer classified as enhancing. H0,b incorporates subtle changes in
intensity time series associated with the contrast injection that happens outside the lesions.
Although the results are promising, there are several concerns with this approach. First, it is
based on the assumption that other than the enhancement in lesions, PPMS and RRMS patients
are similar with respect to T1-weighted MRI. This assumption is partially confirmed by comparing
the distribution of 3rd and 4th PC scores for voxels outside the lesion masks. As displayed by the
blue and gray dots in Figure 10, despite the between-sample variation, the bivariate PC scores
have a similar shape for all samples. Second, only a small number of PPMS images are available in
our study but larger future studies of DCE-MRI in patients with PPMS will be useful for refining
the definition of non-enhancement through the null hypothesis H0,b.
With all these candidate null hypotheses, when a new dataset is ready for testing, we could
either select one of them according to the reliability of segmentation information, or we can test
the data under all the null hypotheses and combine the results. We do not provide a strict criterion
on how to draw final conclusion from all the results of the null hypothesis, as this is not the main
aim of our paper. The goal is to make simple yes-or-no decisions while understanding what “yes”
means and to understand the scientific problem from several new angles.
5 Conclusions
We have introduced the problem of identifying lesion voxels that enhance in DCE-MRI of MS
patients. This problem is very complex because of the lack of a gold standard or precise definition
of null hypothesis. This eminently qualitative hypothesis is then slowly transformed into a quan-
titative hypothesis using a close inter-play between data, statistical testing, and hard to quantify
biological anatomy priors.
We proposed five ways of defining the null hypothesis for “non-enhancement” and estimating
the corresponding null distributions. All five definitions aim at searching for data characteristics
that comprehensively approximate normal behavior. While some are visit-specific, others use
the entire sample. Some null distribution estimation procedures use segmentation information.
When applied to data from subject 1, all of the above null hypotheses identify voxels in the
enhancing lesions and confirm the existence of an additional (previously unknown) active lesion
in the frontal lobe that was not detected by Lesion-TOADS. However, differences in specificity
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across the methods result in labeling of fewer or more NAWM voxels and voxels outside the WM
mask as enhancing. We have found that many false positives are in the meninges and interstitial
spaces and incorporating this anatomical information improves results.
We note that defining a null hypothesis is fundamentally different from the problem of multiple
testing where a null hypothesis exists. To account for multiple testing we used Bonferroni cor-
rection instead of FDR (Benjamini & Yekutieli, 2001) because there is a one-to-one relationship
between FDR and FWER α level. Neither of them solves the fundamental problem that we we do
not know what the null hypothesis actually is. Instead we proposed a spectrum of null hypothe-
ses that can be explored, criticized, and refined. We have labeled this paradigm the “soft null
hypothesis”, to emphasize that data can and should be used to define and refine null hypotheses.
SUPPLEMENTAL MATERIALS
Title: Supplementary Materials for Soft Null Hypothesis Testing in Lesion Detection (PDF)
A. Comparison of the Smoothing Methods on PLPCs Results comparing the simple lin-
ear interpolation described in Section 2 of the manuscript and the spline smoothing method
for raw intensity curves for each voxel. We conduct principal component analysis on intensity
curves that are smoothed with the two methods. The resulting population level principal
components (PLPCs) are shown to be similar.
B. Results for Clustering Analysis Detailed results of clustering analysis based on the 3rd
and 4th PC scores. We cluster the voxels by fitting a mixture normal distribution with
3 ∼ 6 components and compare the results. We also take the fitted distributions as null
distribution and obtain the testing results with respect to the null.
C. Soft Null Hypothesis Test for Subject 2 Testing results for a second subject under the
soft null procedure.
25
Hosted by The Berkeley Electronic Press
References
Benjamini, Y., & Yekutieli, D. 2001. The control of the false discovery rate in multiple testing
under dependency. The Annals of Statistics, 29, 1165–1188.
Capra, R., Marciano, N., Vignolo, L.A., Chiesa, A., & Gasparotti, R. 1992. Gadolinium-pentetic
acid magnetic resonance imaging in patients with relapsing remitting multiple sclerosis. Archives
of Neurology, Chicago, 49, 687–689.
Carass, A. 2007. A joint registration and segmentation approach to skull stripping. Proceedings
of the 2007 IEEE International Symposium on Biomedical Imaging: From Nano to Macro.
Washington, DC,USA. April 12-16, 2007, 656–659.
Davidian, M., & Giltinan, D.M. 1995. Nonlinear models for repeated measurement data. Chapman
& Hall/CRC0412983419.
Efron, B. 2004. Large-scale simultaneous hypothesis testing: the choice of a null hypothesis.
Journal of the American Statistical Association, 99, 96–104.
Efron, B. 2007. Correlation and large-scale simultaneous significance testing. Journal of the
American Statistical Association, 102, 93–103.
Fox, R.J., Bethoux, F., Goldman, M.D., & Cohen, J.A. 2006. Multiple sclerosis: advances in
understanding, diagnosing, and treating the underlying disease. Cleveland Clinic Journal of
Medicine, 73, 91–102.
Gaita´n, M.I., Shea, C.D., Evangelou, I.E., Stone, R.D., Fenton, K.M., Bielekova, B., Massacesi,
L., & Reich, D.S. 2011. Evolution of the blood–brain barrier in newly forming multiple sclerosis
lesions. Annals of Neurology.
Li, X., Rooney, W. D., & Springer, C. S. 2005. A unified magnetic resonance imaging phar-
macokinetic theory: intravascular and extracellular contrast reagents. Magnetic Resonance in
Medicine, 54, 1351–1359.
Lublin, F.D., & Reingold, S.C. 1996. Defining the clinical course of multiple sclerosis. Neurology,
46, 907–911.
26
http://biostats.bepress.com/jhubiostat/paper257
Shiee, N., Bazin, P.L., Reich, D., & Pham, D.L. 2010. A topology preserving approach to the
segmentation of brain images with multiple sclerosis lesions. Neuroimage, 49, 1524–1535.
Shinohara, R.T., Crainiceanu, C.M., Gaita´n, M. I., Caffo, B.S., & Reich, D. 2011. Population-wide
principal component-based quantification of blood-brain-barrier dynamics in multiple sclerosis.
Neuroimage, 57, 1430–46.
Tofts, P.S., Brix, G., Buckley, D.L., Evelhoch, J.L., Henderson, E., Knopp, M.V., Larsson, H.B.W.,
Lee, T., Mayr, N.A., Parker, G.J.M., Port, R.E., Taylor, J., & Weisskoff, R.M. 1999. Estimating
kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer:
standardized quantities and symbols. Journal of Magnetic Resonance Imaging, 10, 223–232.
Yankeelov, T.E., Luci, J.J., Lepage, M., Li, R., Debusk, L., Lin, P.C., Price, R.R., & Gore,
J.C. 2005. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input
function: a reference region model. Magnetic resonance imaging, 23, 519–29.
27
Hosted by The Berkeley Electronic Press
